# Glycosaminoglycan–Protein Interactions: The First Draft of the Glycosaminoglycan Interactome

Sylvain D Vallet, Olivier Clerc, Sylvie Ricard-Blum

► To cite this version:

Sylvain D Vallet, Olivier Clerc, Sylvie Ricard-Blum. Glycosaminoglycan–Protein Interactions: The First Draft of the Glycosaminoglycan Interactome. Journal of Histochemistry and Cytochemistry, 2021, 69 (2), pp.93-104. 10.1369/0022155420946403. hal-05000497

HAL Id: hal-05000497

https://hal.science/hal-05000497v1

Submitted on 21 Mar 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

<figure><img src="image_3.png" /></figure>

# Glycosaminoglycan-Protein Interactions: The First Draft of the Glycosaminoglycan Interactome

Sylvain D. Vallet, Olivier Clerc, and Sylvie Ricard-Blum

Univ Lyon, University Claude Bernard Lyon 1, CNRS, INSA Lyon, CPE, Institute of Molecular and Supramolecular Chemistry and Biochemistry, UMR 5246, Villeurbanne Cedex, France (SDV, OC, SR-B)

## Summary

The six mammalian glycosaminoglycans (GAGs), chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate, hyaluronan, and keratan sulfate, are linear polysaccharides. Except for hyaluronan, they are sulfated to various extent, and covalently attached to proteins to form proteoglycans. GAGs interact with growth factors, morphogens, chemokines, extracellular matrix proteins and their bioactive fragments, receptors, lipoproteins, and pathogens. These interactions mediate their functions, from embryonic development to extracellular matrix assembly and regulation of cell signaling in various physiological and pathological contexts such as angiogenesis, cancer, neurodegenerative diseases, and infections. We give an overview of GAG-protein interactions (i.e., specificity and chemical features of GAG- and protein-binding sequences), and review the available GAG-protein interaction networks. We also provide the first comprehensive draft of the GAG interactome composed of 832 biomolecules (827 proteins and five GAGs) and 932 protein-GAG interactions. This network is a scaffold, which in the future should integrate structures of GAG-protein complexes, quantitative data of the abundance of GAGs in tissues to build tissue-specific interactomes, and GAG interactions with metal ions such as calcium, which plays a major role in the assembly of the extracellular matrix and its interactions with cells. This contextualized interactome will be useful to identify druggable GAG-protein interactions for therapeutic purpose. (J Histochem Cytochem 69: 93–104, 2021)

## Keywords

chondroitin sulfate, dermatan sulfate, extracellular matrix, glycosaminoglycan, heparan sulfate, heparin, hyaluronan, interaction networks, keratan sulfate, proteoglycan

## Introduction

The six mammalian glycosaminoglycans (GAGs), namely, chondroitin sulfate (CS), dermatan sulfate (DS), heparin (HP), heparan sulfate (HS),¹,² hyaluronan (HA),³ and keratan sulfate (KS),⁴,⁵ are linear polysaccharides made of disaccharide repeats. These disaccharides are composed of an uronic acid and an hexosamine,⁶ except for KS, which lacks the uronic acid and consists of a sulfated poly-N-acetyl lactosamine chain made of D-galactose and N-acetylgalactosamine.⁵ All mammalian GAGs, except HA, are sulfated to various extent and in various positions, and are covalently attached to proteins to form proteoglycans. Epimerization of glucuronic acid to iduronic acid occurs in DS, HP, and HS. There are

in total 202 unique mammalian disaccharides of mammalian GAGs, including 48 HS-based disaccharides,⁷ which highlights their structural diversity and variability. CS is composed of disaccharide units containing D-glucuronic acid and N-acetylgalactosamine. The epimerization of glucuronic acid to iduronic acid leads to the

Received for publication April 23, 2020; accepted July 6, 2020.

## Corresponding Author:

Sylvie Ricard-Blum, Univ Lyon, University Claude Bernard Lyon 1, CNRS, INSA Lyon, CPE, Institute of Molecular and Supramolecular Chemistry and Biochemistry, UMR 5246, Lederer Building, 43 Boulevard du 11 novembre 1918, 69622 Villeurbanne Cedex, France.

E-mail: sylvie.ricard-blum@univ-lyon1.fr
formation of DS disaccharides. The sulfation of CS/DS in several positions generates six disaccharide units (CS-A-E), and these different sulfation patterns, referred to as “wobble CS/DS oligosaccharide motifs,” generate structural diversity at the CS–DS hybrid chain level.⁸,⁹ The organization of HS chains in highly sulfated and iduronic acid–enriched domains (S or NS domains) interspersed with non-sulfated domains (NA or NAc domains) provides them with additional structural diversity.¹

The GAG chains, ranging from a few kDa to over a 100 kDa, contribute to the physicochemical properties and biological functions of proteoglycans.⁶,¹⁰,¹¹ HS, for example, affects the conformation, stability, and diffusion of proteins.¹ Other unique sulfated GAGs with biological functions such as anticoagulant activity and neurite outgrowth–promoting activity exist in primitive chordates, but they are not discussed in this review.¹²,¹³

GAGs play numerous biological roles, ranging from embryonic development,¹⁴,¹⁵ extracellular matrix (ECM) assembly to the regulation of cell signaling¹,⁶ in various physiological and pathological contexts such as angiogenesis,¹⁶,¹⁷ cancer,¹⁸,¹⁹ inflammation,¹⁸,²⁰ neural development,²¹ neurodegenerative diseases,²²,²³ and host–pathogen interactions.²⁴ These roles are mediated by the interactions of GAGs with a variety of proteins, including soluble proteins (growth factors, morphogens, and chemokines²⁵,²⁶), ECM proteins and bioactive fragments, membrane receptors such as integrins,²⁷,²⁸ and lipoproteins.²⁹ GAGs also bind to numerous pathogens, including viruses,³⁰ bacteria,³¹ parasites,³²,³³ and fungi.²⁴,³⁴ The interaction of HS with a number of viruses contributes to their attachment to the host cells or to their increased concentration at the cell surface, whereas HS proteoglycans may serve as entry receptors for some viruses.³⁵ It has been recently reported that HP binds to the spike glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV), and to both monomeric and trimeric spike of SARS-CoV-2, responsible for the COVID-19 pandemic.³⁶ The interaction between HP and the SARS-CoV-2 Spike S1 protein is mediated by the receptor-binding domain of the protein.³⁷ GAG–protein interactions may be targeted for therapeutic purpose as shown for HP– and HS–protein interactions³⁸,³⁹ and microbial GAG–protein interactions.⁴⁰

We give here an overview of the molecular characterization of GAG–protein interactions (i.e., specificity and chemical features of GAG and protein-binding sequences), and review the available GAG–protein interaction networks. We also provide the first comprehensive draft of the GAG interactome composed of 827 proteins and 932 protein–GAG interactions. This network is a scaffold, which in the future should integrate

structures of GAG–protein complexes, quantitative data on the abundance of GAGs in tissues to build tissue-specific interactomes, and GAG interactions with metal ions such as calcium, which plays a major role in the ECM assembly and in ECM–cell interactions. This contextualized interactome will be useful to identify druggable GAG–protein interactions for therapeutic purpose. The major perspectives and challenges to overcome to reach this goal are presented in the conclusion.

## Glycosaminoglycan–Protein Interactions

The methods to identify and characterize GAG interactions were recently reviewed.⁶ They include label-free techniques monitoring interactions in real time such as surface plasmon resonance and bio-layer interferometry,⁴¹ solid-phase binding assays, protein arrays probed with GAGs,⁴² and GAG arrays probed with proteins.⁴¹,⁴³⁻⁴⁵ Very large interaction data sets are not available for GAG interactions because high-throughput techniques used to collect interaction data are gene-centric (two hybrid approaches) or protein-centric (affinity-purification-mass spectrometry). Libraries of GAG-like oligosaccharides have been synthesized either chemically and/or enzymatically, and may be used to design GAG microarrays for studying GAG–protein interactions.⁴³ A cell-based library of displayed GAGs, the GAGOme, has been developed for cell-binding assays and the assembly of GAG microarrays, and the identification of further GAG-binding partners.⁴⁶ A number of GAG–protein interactions experimentally supported has been manually curated according to the curation rules of the International Molecular Exchange (IMEx) consortium⁴⁷ and stored in the publicly and freely available interaction database MatrixDB (http://matrixdb.univ-lyon1.fr/) that we have developed.⁴⁸⁻⁵⁰ MatrixDB, the ECM interaction database,⁴⁸,⁴⁹ contains GAG–protein and protein–protein interaction data manually curated from literature, and has been recently updated with a focus on GAGs.⁵⁰

GAG–protein interactions are driven by the features of GAGs (chemical groups, length, and conformation) and of their protein partners (amino acid residues in linear sequences or three-dimensional [3D] structures). The characterization of binding interfaces is required to decipher the molecular mechanisms underlying GAG–protein interactions, their specificity, and their biological functions. The various modes of interaction between HS and its protein partners have been reviewed.⁶,²⁹,⁵¹ The basic consensus sequences, X-B-B-X-B-X and X-B-B-X-X-B-X, where B is an arginine or lysine residue, and X is a hydrophobic amino acid, identified by Cardin
and Weintraub⁵² and called CW motifs, are found in HP-
or HS-binding proteins. However, the network analysis
of the amino acid sequences of 437 HP-binding pro-
teins has shown that HP-binding sequences may be
composed of numerous, short, spaced, basic amino
acid sequences forming in a concerted fashion a 3D
arrangement on the protein surface rather than linear
basic sequences.⁵³ The fact that HP-binding sites are
only made of stretches of contiguous arginine and
lysine residues has also been challenged by the finding
that numerous ionic and non-ionic amino acid residues
contribute to the specificity of GAG-binding sites. The
uncharged, polar, residues, asparagine or glutamine,
are involved in the formation and specificity of GAG-
binding sites. Highly specific and nonspecific GAG-
protein interactions can be discriminated by identifying
"hot spots" in GAG-binding sites. (i.e., neutral loci among
arginine/lysine residues that present high electrostatic
potential).³⁸ This will have direct applications in the
identification of druggable GAG-protein interactions,
the design of GAGs and GAG mimetics as potential
drugs, and in the identification of the GAG interactome
by computational analysis.³⁸ HP-binding sites may be
partially disordered, and we have shown that the asso-
ciation rate of proteins with HP is positively correlated
with the percentage of disordered residues in HP-binding
sites.⁵⁴

More than 75 GAG-protein complexes are available
in the Protein Data Bank,⁷ and the structural biology of
the HP interactome based on GAG-protein complexes
has been reviewed.⁵⁵ When no structural experimental
data are available, and when the sequence of GAG
oligosaccharides interacting with proteins is known, it
is possible to build their 3D models, and to use them
for docking onto the 3D structure of their protein part-
ners to determine the chemical features of GAGs and
amino acid residues (or domains) of proteins involved
in the interactions. Coarse-grained models of GAGs
have been generated,⁵⁶,⁵⁷ and quantum mechanics,
molecular mechanics and dynamics, coarse graining
and docking methods have been used for the multi-
scale modeling of GAG structure, from monosaccha-
rides to GAG chains.⁵⁸

We have designed a pipeline to build 3D models of
GAG oligosaccharides from their GlycoCT codes, a
machine-readable encoding scheme for complex car-
bohydrates,⁵⁹ with the GAG builder tool we developed.
This tool is based on a repertoire of conformations
experimentally validated by data extracted from GAG-
protein crystals.⁷ A converter (the CT23D converter)
automatically translates the GlycoCT code of a GAG
sequence into the input file required for GAG builder.⁷
which is freely available on the web site of MatrixDB
database.⁵⁰ We have shown that the Φ and Ψ torsion

angles of the HP/HS and HA oligosaccharides co-
crystallized with proteins are clustered into two major
areas, emphasizing the role of GAG conformation in
protein binding.⁷

The sulfation patterns of GAGs, referred to as the
sulfation codes, are key features for the molecular rec-
ognition of GAG partners. Alterations of the degree of
GAG sulfation are often associated with disorders such
as degenerative diseases and malignant neoplasms.⁶⁰
The chemical modifications of HS chains govern their
specific interactions with a number of proteins, but their
organization into sulfated and N-acetylated domains also
contributes to the specificity of protein interactions.²⁹
The role of HS organization has been shown for its
interaction with endostatin, the C-terminal fragment
of collagen XVIII, which binds to a 10/12-mer contain-
ing two N-sulfated regions separated by at least one
N-acetylated glucosamine unit.⁶¹

Another parameter contributing to the specificity of GAG-protein interactions is the internal mobility of GAG chains. The internal mobility of sulfated domains of HS chains is mostly due to the conformational flexibility of iduronic acid residues, but the sulfated domains are less flexible than the non-sulfated ones.⁶² The organization of HS chains in domains of variable flexibility allows multiple interactions to occur along the same chain.

Docking combined with molecular dynamics simula-
tions has been used to investigate GAG-protein
complexes⁶³ such as those formed with growth factors
(e.g., vascular endothelial growth factor-A-HP),⁶⁴ with
ECM proteins such as those formed by procollagen
C-proteinase-enhancer-1 with several GAGs⁶⁵ or by
ECM bioactive fragments such as the propeptide of
lysyl oxidase with a HP hexasaccharide.⁶⁶ A bench-
marking study, including eight docking softwares for 28
GAG-protein complexes, has concluded that the com-
bination of several molecular docking programs and
other modeling approaches such as molecular dynamic
improves the prediction and evaluation of GAG-binding
poses.⁶⁷ Computational approaches are valuable tools
to address the following points: “does a protein bind to
GAG,” “where does the GAG bind,” “is the GAG-protein
complex stable,” and “what is the most optimal GAG
binding sequence” as summarized in the flowchart
designed by Sankaranarayanan et al.⁶⁸ The affinity and
kinetics of GAG interactions also provide information.
Matrisome-associated proteins (e.g., growth factors)
form transient complexes with HP but bind to this GAG
with a higher affinity than core matrisome proteins.⁵⁴
Kinetics and affinity can be used to rank interactions in
networks. We have integrated them in the interaction
network of an endogenous angiogenesis inhibitor, end-
ostatin, which is a HP-binding protein interacting with
other HP-binding proteins at the surface of endothelial cells.⁵⁴

## The First Draft of the Glycosaminoglycan Interactome

Several networks focused on a specific GAG, a subset of GAG-binding proteins, or a biological process (e.g., angiogenesis as described above)⁵⁴ have been built. HP and HS interactions with angiogenesis regulators have been collected to create the “angiogenesis gly-comic interactome” comprising 56 proteins, including growth factors, proangiogenic receptors, angiogenesis inhibitors, and effectors.¹⁶ An interaction network of HP/HS was built in 2018 using MatrixDB data. It contained 262 interactions of HP/HS with ECM proteins, ECM bioactive fragments, cytokines, growth factors, proteins from the complement system, membrane proteins such as integrins, and intracellular proteins.⁶ The most com-prehensive HP/HS available so far was the HP/HS interactome containing 435 human proteins binding to HP or HS, which was generated by combining data from the literature and affinity proteomics experiments performed on plasma membrane-enriched fractions isolated from rat liver.⁶⁹

MatrixDB data have also been used to build an inter-action network comprising five of the six mammalian GAGs, 135 proteins, and 211 GAG-protein interactions.⁴¹ In this network, 60.5% of HP partners, 38.5% of HA partners, and 20% of CS partners bound only to HP, HA, and CS respectively, whereas none of the DS partners interacted only with DS.⁴¹ HP was thus the GAG with the highest number of specific protein part-ners, and DS had no specific protein partners. In con-trast, less than 2% of HP partners interacted with five GAGs, whereas 13% to 15% of CS, DS, and HA part-ners bound to five GAGs.⁴¹

GAGs have been reported to bind to more than 500 proteins.³⁸ To generate the first comprehensive draft of the mammalian GAG interactome, we used the road-map we designed to build extracellular and pericellular protein-GAG interaction networks.⁷⁰ Several sources of interaction data were combined to build the protein network of the six mammalian GAGs (i.e., CS, DS, HS/HP, HA and KS). HP and HS interactions were clustered because these GAGs share the same disac-charide unit, and HP is often used as a model for HS. Partners of KS (217 proteins), CS A (24 proteins), and HA (six proteins) identified using protein arrays and biotinylated GAGs,⁴² and of HP/HS identified by affinity chromatography-mass spectrometry⁶⁹ were included in the GAG interaction data set together with the CS-binding proteins identified in the central nervous system.⁷¹ Further manual curation of the literature was

performed with a focus on ECM proteins. UniProtKB⁷² and Gene Ontology (GO) database⁷³ were queried using keywords and GO terms related to GAG binding (e.g., KW-0358 heparin binding, and GO:1904399 heparan sulfate binding).

The resulting network is the first comprehensive interactome of the six mammalian GAGs (HP and HS being clustered). It comprises 832 biomolecules (827 proteins and five GAGs) and 932 protein-GAG interactions (Fig. 1). The experimental settings used to identify interactions are detailed in the articles listed by their PubMed reference number (PMID) in Supplementary Table S1. When an interaction has been reported in several studies, all the publications are listed. HP/HS, which are the most extensively studied GAGs; have 580 partners, KS and CS bind to 218 and 72 proteins, respectively; and HA and DS have the lowest number of partners (43 and 19, respectively). About 89% of the HP-/HS-binding proteins interact only with HP/HS, 85% of KS-binding proteins interact only with KS, 63% of HA partners bind only to HA, and 26% of CS partners bind specifically to CS (Fig. 2). In contrast, none of the partners of DS binds specifically to it (Fig. 2) as previously reported for a smaller GAG network.⁴¹ HP, HS, and KS have thus the highest number of specific protein partners, whereas DS has no specific protein partners but has the highest percentage of partners able to bind to four (26%) or five (5%) GAGs. However, it is difficult to draw firm conclusions on the specificity of the GAG partners given that binding assays have been performed with different sets of proteins for each GAG, and that negative results (i.e., lack of binding to a protein) are not recorded in most databases. This emphasizes the need to design proteome-wide binding assays to increase GAG interactome coverage.

The number of partners common to GAG pairs is displayed in Fig. 3. Although HA is not sulfated, it has eight partners in common with HP/HS, which are highly sulfated. The proteins binding to three, four, of five GAGs are displayed in Fig. 1 and Supplementary Table S2. Eleven proteins bind to three GAGs, including ECM proteins (collagens I, IV, and VI, and thrombospondin-1), a matricryptin of collagen XVIII (endostatin), and proteins involved in nervous system development (netrin receptor DCC, and ephrins A1 and A3). Five proteins interact with four GAGs, an ECM protein, procollagen C-proteinase enhancer-1, cathepsin K, tumor necrosis factor-inducible gene 6 protein, a multifunctional protein with anti-inflammatory and tissue-protective properties,⁷⁴ a β-amyloid peptide, and the propeptide of lysyl oxidase (Fig. 1 and Supplementary Table S2). A single protein, the insulin-like growth factor-binding protein 7, binds to all GAGs (Fig. 1 and Supplementary Table S2). Because the partners of
<figure><img src="image_4.png" /><figcaption>**Figure 1.** The interactome of the six mammalian glycosaminoglycans (GAGs) comprising 827 proteins and 932 GAG-protein interactions (72 for chondroitin sulfate, 19 for dermatan sulfate, 580 for heparin/heparan sulfate, 43 for hyaluronan, and 218 for keratan sulfate). The partners of GAGs are displayed according to the number of GAGs they interact with. The colored nodes, located at the periphery of the network, bind only to the GAG with the same color, the square correspond to proteins interacting with two GAGs, and the two inner circles correspond to proteins interacting with three (light gray) and four (dark) GAGs. The protein, which binds to all GAGs, is at the center of the network (CPX: complex, i.e., multimeric proteins, PFRAG: bioactive protein fragments, e.g., COL18A1 PFRAG1: endostatin).</figcaption></figure>

GAGs may interact with each other in vivo, we have added them to build a comprehensive GAG network, including not only GAG-protein interactions but also protein interactions between GAG partners. Protein-protein interactions were collected by manual curation of the literature, and by querying MatrixDB, the Adhésome network (http://adhesome.org)⁷⁵ and the Bioplex 2.0 data set.⁷⁶ The resulting network comprises

827 proteins and 2240 interactions (Supplementary Fig. S1 and Supplementary Table S1).

Enrichment analyses of the GAG interactome were carried out using the functional enrichment analysis tool FunRich, and FunRich database as background.⁷⁷ The full report of these analyses is included in Supplementary Table S3. They show that 55% of GAG partners are extracellular, 30% are located in plasma
<figure><img src="image_5.png" /><figcaption>**Figure 2.** Specific and common protein partners of the six GAGs. The percentages of partners, which bind to one (red), two (green), three (yellow), four (blue) or five (black) GAGs, are indicated for each GAG. The total number of partners of each GAG is indicated in brackets. Abbreviations: GAGs, glycosaminoglycans; CS, chondroitin sulfate; DS, dermatan sulfate; HA, hyaluronan; HP, heparin; HS, heparan sulfate; KS, keratan sulfate.</figcaption></figure>

membranes, 27% in exosomes, and 20% in lysosomes. These cellular component annotations are significantly enriched in the GAG interactome ($p<0.001$). Several molecular functions are also significantly enriched in GAG partners ($p<0.001$), but they concern less than 10% of them (ECM structural constituent: 8%, serine/threonine kinase activity: 5%) or less than 5% of them. No protein domain was significantly overrepresented in numerous GAG partners, except for the presence of a signal peptide in 62% of GAG partners ($p<0.001$), indicating that most GAG partners are secreted proteins. The epidermal growth factor domain is the next most abundant domain in GAG partners, but it is present in only 7% of them ($p<0.001$), followed by the tyrosine kinase, catalytic domain (TyrKc; 5%, $p<0.001$).

The biological processes significantly enriched ($p<0.001$) in the GAG interactome are signal transduction (36% of the GAG partners), cell communication (34%), cell growth and/or maintenance (12%), and immune response (10%). Pathway analysis was then performed using Reactome.⁷⁸,⁷⁹ The major significant pathways identified by Reactome are displayed in Fig. 4, and the 25 most relevant pathways sorted by *p* value ($10^{-16}<*p*<10^{-13}$) are listed in Supplementary Table S4. They include pathways related to ECM organization (assembly of collagen fibrils and other multimeric structures, collagen and ECM degradation, collagen formation and chain trimerization, ECM proteoglycans, non-integrin membrane–ECM interactions, and integrin cell surface interactions), signal transduction (phospholipase C-mediated cascade, FGFR2 [fibroblast
<figure><img src="image_6.png" /><figcaption>**Figure 3.** The Venn diagram showing the number of specific partners of individual GAGs, and the number of protein partners shared by two, three, four, or five GAGs. Partners interacting with three, four, or five GAGs are listed in Supplementary Table S2. The diagram was built with a web-service (http://bioinformatics.psb.ugent.be/webtools/Venn/). Abbreviations: GAGs, glycosaminoglycans; CS, chondroitin sulfate; DS, dermatan sulfate; HA, hyaluronan; HP, heparin; HS, heparan sulfate; KS, keratan sulfate.</figcaption></figure>

growth factor receptor 2], FGFR2 ligand binding and activation, PI3K/AKT signaling, PI3K/AKT signaling in cancer, chemokine receptors and signaling by receptor tyrosine kinases), hemostasis (platelet degranulation, and response to elevated platelet cytosolic Ca²⁺), developmental biology (nervous system development, axon guidance, EPH-ephrin-mediated repulsion of cells), and metabolism of proteins (posttranslational protein phosphorylation, and regulation of insulin-like growth factor [IGF] transport and uptake by IGF-binding proteins).

Several transcription factors regulating the expression of GAG partners are significantly enriched (*p*<0.001) in the GAG interactome, including hepatocyte nuclear factor 4-alpha (27%), nuclear factor 1 C-type (21%), and transcription factor E2-alpha involved in the initiation of neuronal differentiation (TCF3, 19%) (Supplementary Table S3). The analysis of GAG partners using FunRich

and the Catalogue of Somatic Mutations in Cancer, a comprehensive resource for exploring the effect of somatic mutations in human cancer,⁸⁰ shows a significant enrichment (*p*<0.001) in somatic mutations associated with the central nervous system (74%), skin (71%), prostate (60%), and hematopoietic and lymphatic tissues (56%).

In conclusion, the first draft of the GAG interactome is a scaffold which should integrate further data in the future. The integration of quantitative data on the presence/abundance of GAGs in healthy and diseased tissues or biological fluids (i.e., glycosaminoglycomics data)⁸¹ would allow us to generate tissue-specific and disease-specific GAG networks. Methods and standards to analyze GAGs are under development, and will speed up the collection and use of glycosaminoglycomics data in the coming years.⁸²⁻⁸⁴ Structural analyses have been done for individual complexes⁵⁵
<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>

reactome

<caption>**Figure 4.** A human genome-wide overview of the results of the pathway analysis of the glycosaminoglycan (GAG) interactome using Reactome.<sup>78,79</sup> “Reactome pathways are arranged in a hierarchy. The center of each of the circular ‘bursts’ is the root of one top-level pathway. Each step away from the center represents the next level lower in the pathway hierarchy.”<sup>78</sup> The size of the nodes is proportional to the number of physical entities (proteins, complexes, chemicals) it contains. The color code denotes overrepresentation of pathways. Light color indicates that the corresponding pathways are not significantly overrepresented in the GAG interactome.</caption>

but not at the GAG interactome scale. Experimental data are available in the Protein Data Bank for about 75 GAG-protein complexes,⁷ but additional data could be generated using docking experiments when the 3D structure of GAG-binding proteins is known. Three-dimensional models of GAG sequences binding to proteins could also be built using several approaches as described above. This would be useful to decipher the glycocode resulting from the combinatorial of chemical groups, mostly sulfate groups, along GAG chains.

It would be interesting to include the interactions of GAG-metal ion interactions in the next version of the GAG interactome. Indeed, GAGs can bind to metal ions associated with proteins or to metal ions in solution, and metal ions can modulate the specificity and affinity of protein-GAG interactions.⁸⁵ The binding of prion protein to GAGs is stabilized by Cu²⁺ or Zn²⁺ ions, and the interaction of endostatin with HS is increased in the presence of Zn²⁺ ions.⁸⁶ In addition, HP binds to calcium,⁸⁵ which plays a major role in ECM assembly and functions,⁸⁷ and in ECM-cell interactions<sup>88</sup> as reported for syndecans, which interact with transient receptor potential channels involved in Ca²⁺ entry mechanisms and can regulate them.⁸⁹ Here again, modeling approaches could provide new insights on the effects of ions on protein-GAG interactions as

shown for the complex formed by the ECM protein procollagen C-proteinase enhancer-1 and GAG oligosaccharides.⁶⁵ It would be also crucial to determine the role of the proteoglycan protein cores in GAG-protein interactions to better understand the mechanisms of GAG-protein interactions in vivo. Last, partners of the unique sulfated GAGs found in primitive chordates, which have important biological functions such as anticoagulant activity and neurite outgrowth promoting activity,¹²,¹³ should be added to the mammalian GAG interactome.

## Competing Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Author Contributions

SDV performed literature curation and database searches, and designed the figures; OC retrieved glycosaminoglycan (GAG)-protein interactions from Gene Ontology and UniProtKB, assembled the interaction data set, and implemented new GAG features in MatrixDB database; and SR-B manually checked retrieved GAG interaction data, performed enrichment and pathway analyses of the GAG interactome, and wrote the manuscript. All authors have read and approved the final manuscript.
## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work performed by the authors was supported by the "Fondation pour la Recherche Médicale," France (Grant No. DBI20141231336 to S.R.-B.), the Institut Français de Bioinformatique (ANR-11-INBS-0013), Glycomatrix project, call 2015 to S.R.-B. and O.C., and the Groupement de Recherche (GDR) GagoSciences (CNRS, GDR 3739, Structure, Fonction et Régulation des Glycosaminoglycanes to S.R.-B., S.D.V., and O.C.).

## Literature Cited

1. Gallagher J. Fell-Muir lecture: heparan sulphate and the art of cell regulation: a polymer chain conducts the protein orchestra. Int J Exp Pathol. 2015;96(4):203-31.

2. Li J-P, Kusche-Gullberg M. Heparan sulfate: biosynthesis, structure, and function. Int Rev Cell Mol Biol. 2016;325:215-73.

3. Garantziotis S, Savani RC. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019;78-79:1-10.

4. Caterson B, Melrose J. Keratan sulfate, a complex glycosaminoglycan with unique functional capability. Glycobiology. 2018;28(4):182-206.

5. Pomin VH. Keratan sulfate: an up-to-date review. Int J Biol Macromol. 2015;72:282-9.

6. Karamanos NK, Piperigkou Z, Theocharis AD, Watanabe H, Franchi M, Baud S, Brézillon S, Götte M, Passi A, Vigetti D, Ricard-Blum S, Sanderson RD, Neill T, Izzo RV. Proteoglycan chemical diversity drives multifunctional cell regulation and therapeutics. Chem Rev. 2018 Sep 26;118(18):9152-232.

7. Clerc O, Mariethoz J, Rivet A, Lisacek F, Pérez S, Ricard-Blum S. A pipeline to translate glycosaminoglycan sequences into 3D models. Application to the exploration of glycosaminoglycan conformational space. Glycobiology. 2019 Jan 1;29(1):36-44.

8. Purushothaman A, Sugahara K, Faissner A. Chondroitin sulfate "wobble motifs" modulate maintenance and differentiation of neural stem cells and their progeny. J Biol Chem. 2012;287(5):2935-42.

9. Kastana P, Choleva E, Poimenidi E, Karamanos N, Sugahara K, Papadimitriou E. Insight into the role of chondroitin sulfate E in angiogenesis. FEBS J. 2019;286 (15):2921-36.

10. Izzo RV, Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015;42:11-55.

11. Pomin VH, Mulloy B. Glycosaminoglycans and proteoglycans. Pharmaceuticals (Basel). 2018 Feb 27;11(1):27.

12. Pavão MSG. Glycosaminoglycans analogs from marine invertebrates: structure, biological effects, and potential as new therapeutics. Front Cell Infect Microbiol. 2014;4:123.

13. Karamanou K, Espinosa DCR, Fortuna-Costa A, Pavão MSG. Biological function of unique sulfated glycosaminoglycans in primitive chordates. Glycoconj J. 2017;34(3):277-83.

14. Kramer KL. Specific sides to multifaceted glycosaminoglycans are observed in embryonic development. Semin Cell Dev Biol. 2010;21(6):631-7.

15. Poulain FE, Yost HJ. Heparan sulfate proteoglycans: a sugar code for vertebrate development? Development. 2015 Oct 15;142(20):3456-67.

16. Chiodelli P, Bugatti A, Urbinati C, Rusnati M. Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutic use. Molecules. 2015 Apr 10;20(4):6342-88.

17. Spinelli FM, Vitale DL, Demarchi G, Cristina C, Alaniz L. The immunological effect of hyaluronan in tumor angiogenesis. Clin Transl Immunology. 2015 Dec 4;4(12):e52.

18. Morla S. Glycosaminoglycans and glycosaminoglycan mimetics in cancer and inflammation. Int J Mol Sci. 2019 Apr 22;20(8):1963.

19. Vitale D, Kumar Katakam S, Greve B, Jang B, Oh ES, Alaniz L, Götte M. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J. 2019;286(15):2870-82.

20. Johnson P, Arif AA, Lee-Sayer SSM, Dong Y. Hyaluronan and its interactions with immune cells in the healthy and inflamed lung. Front Immunol. 2018;9:2787.

21. Saied-Santiago K, Bülow HE. Diverse roles for glycosaminoglycans in neural patterning. Dev Dyn. 2018; 247(1):54-74.

22. Quittot N, Sebastiao M, Bourgault S. Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance. Biochem Cell Biol. 2017;95(3):329-37.

23. Nishitsuji K, Uchimura K. Sulfated glycosaminoglycans in protein aggregation diseases. Glycoconj J. 2017;34(4):453-66.

24. Aquino RS, Park PW. Glycosaminoglycans and infection. Front Biosci (Landmark Ed). 2016 Jun 1;21:1260-77.

25. Monneau Y, Arenzana-Seisdedos F, Lortat-Jacob H. The sweet spot: how GAGs help chemokines guide migrating cells. J Leukoc Biol. 2016;99(6):935-53.

26. Proudfoot AEI, Johnson Z, Bonvin P, Handel TM. Glycosaminoglycan interactions with chemokines add complexity to a complex system. Pharmaceuticals (Basel). 2017 Aug 9;10(3):70.

27. Vorup-Jensen T, Chi L, Gjelstrup LC, Jensen UB, Jewett CA, Xie C, Shimaoka M, Linhardt RJ, Springer TA. Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin. J Biol Chem. 2007 Oct 19;282(42):30869-77.

28. Faye C, Moreau C, Chautard E, Jetne R, Fukai N, Ruggiero F, Humphries MJ, Olsen BR, Ricard-Blum S. Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem. 2009 Aug 14;284(33):22029-40.

29. Xu D, Esko JD. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem. 2014;83:129-57.

30. Ströh LJ, Stehle T. Glycan engagement by viruses: receptor switches and specificity. Annu Rev Virol. 2014 Nov 1;1(1):285-306.

31. García B, Merayo-Lloves J, Martin C, Alcalde I, Quirós LM, Vazquez F. Surface proteoglycans as mediators in
bacterial pathogens infections. Front Microbiol. 2016
Feb 24;7:220.

32. Merida-de-Barros DA, Chaves SP, Belmiro CLR, Wanderley JLM. Leishmaniasis and glycosaminoglycans: a future therapeutic strategy? Parasit Vectors. 2018 Oct 3;11(1):536.

33. Fatoux-Ardore M, Peysselon F, Weiss A, Bastien P, Pratlong F, Ricard-Blum S. Large-scale investigation of Leishmania interaction networks with host extracellular matrix by surface plasmon resonance imaging. Infect Immun. 2014;82(2):594–606.

34. Jinno A, Park PW. Role of glycosaminoglycans in infectious disease. Methods Mol Biol. 2015;1229:567–85.

35. Cagno V, Tseligka ED, Jones ST, Tapparel C. Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? Viruses. 2019 Jul 1;11(7):596.

36. Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, Fu L, Dordick JS, Woods RJ, Zhang F, Linhardt RJ. Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry. bioRxiv. 2020 Apr 15.

37. Mycroft-West C, Su D, Elli S, Guimond S, Miller G, Turnbull J, Yates E, Guerrini M, Fernig D, Lima M, Skidmore M. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational change upon heparin binding. bioRxiv. 2020 Mar 2.

38. Sarkar A, Desai UR. A simple method for discovering druggable, specific glycosaminoglycan-protein systems. Elucidation of key principles from heparin/heparan sulfate-binding proteins. PLoS ONE. 2015;10(10):e0141127.

39. Weiss RJ, Esko JD, Tor Y. Targeting heparin and heparan sulfate protein interactions. Org Biomol Chem. 2017 Jul 21;15(27):5656–68.

40. Almer J, Gesslbauer B, Kungl AJ. Therapeutic strategies to target microbial protein-glycosaminoglycan interactions. Biochem Soc Trans. 2018 Dec 17;46(6):1505–15.

41. Vallet SD, Deddens L, Vonarburg A, Salza R, Faye C. Aranyos A, Thierry-Mieg N, Ricard-Blum S. Strategies for building protein–glycosaminoglycan interaction networks combining SPRi, SPR, and BLI. In: Schasfoort RBM, editor. Handbook of surface plasmon resonance. 2nd ed. London, UK: The Royal Society of Chemistry; 2017. p. 398–414.

42. Conrad AH, Zhang Y, Tasheva ES, Conrad GW. Proteomic analysis of potential keratan sulfate, chondroitin sulfate A, and hyaluronic acid molecular interactions. Invest Ophthalmol Vis Sci. 2010;51(9):4500–15.

43. Faye C, Chautard E, Olsen BR, Ricard-Blum S. The first draft of the endostatin interaction network. J Biol Chem. 2009 Aug 14;284(33):22041–7.

44. Li Z, Feizi T. The neoglycolipid (NGL) technology-based microarrays and future prospects. FEBS Lett. 2018;592(23):3976–91.

45. Pomin VH, Wang X. Synthetic oligosaccharide libraries and microarray technology: a powerful combination for the success of current glycosaminoglycan interac-tomics. ChemMedChem. 2018 Apr 6;13(7):648–61.

46. Chen Y-H, Narimatsu Y, Clausen TM, Gomes C, Karlsson R, Steentoft C, Spliid CB, Gustavsson T, Salanti A, Persson A, Malmström A, Willén D, Ellervik U, Bennett EP, Mao Y, Clausen H, Yang Z. The GAGOme: a cell-based library of displayed glycosaminoglycans. Nat Methods. 2018;15(11):881–8.

47. Orchard S, Kerrien S, Abbani S, Aranda B, Bhate J, Bidwell S, Bridge A, Briganti L, Brinkman FS, Cesareni G, Chatr-aryamontri A, Chautard E, Chen C, Dumousseau M, Goll J, Hancock RE, Hannick LI, Jurisica I, Khadake J, Lynn DJ, Mahadevan U, Perfetto L, Raghunath A, Ricard-Blum S, Roechert B, Salwinski L, Stümpflen V, Tyers M, Uetz P, Xenarios I, Hermjakob H. Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. Nat Methods. 2012;9(4):345–50.

48. Chautard E, Fatoux-Ardore M, Ballut L, Thierry-Mieg N, Ricard-Blum S. MatrixDB, the extracellular matrix interaction database. Nucleic Acids Res. 2011;39 part 2:D235–40.

49. Launay G, Salza R, Multedo D, Thierry-Mieg N, Ricard-Blum S. MatrixDB, the extracellular matrix interaction database: updated content, a new naviga-tor and expanded functionalities. Nucleic Acids Res. 2015;43 part 2:D321–7.

50. Clerc O, Deniaud M, Vallet SD, Naba A, Rivet A, Perez S, Thierry-Mieg N, Ricard-Blum S. MatrixDB: integration of new data with a focus on glycosaminoglycan interac-tions. Nucleic Acids Res. 2019 Jan 8;47(D1):D376–81.

51. Meneghetti MCZ, Hughes AJ, Rudd TR, Nader HB, Powell AK, Yates EA, Lima MA. Heparan sulfate and heparin interactions with proteins. J R Soc Interface. 2015 Sep 6;12(110):20150589.

52. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989;9(1):21–32.

53. Rudd TR, Preston MD, Yates EA. The nature of the conserved basic amino acid sequences found among 437 heparin binding proteins determined by network analysis. Mol Biosyst. 2017;13(5):852–65.

54. Peysselon F, Ricard-Blum S. Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol. 2014;35:73–81.

55. Pomin VH, Mulloy B. Current structural biology of the heparin interactome. Curr Opin Struct Biol. 2015;34:17–25.

56. Sattelle BM, Shakeri J, Cliff MJ, Almond A. Proteoglycans and their heterogeneous glycosaminoglycans at the atomic scale. Biomacromolecules. 2015 Mar 9;16(3):951–61.

57. Samsonov SA, Bichmann L, Pisabarro MT. Coarse-grained model of glycosaminoglycans. J Chem Inf Model. 2015 Jan 26;55(1):114–24.
58. Almond A. Multiscale modeling of glycosaminoglycan structure and dynamics: current methods and challenges. Curr Opin Struct Biol. 2018;50:58–64.

59. Herget S, Ranzinger R, Maass K, Lieth C-WVD. GlycoCT—a unifying sequence format for carbohydrates. Carbohydr Res. 2008 Aug 11;343(12):2162–71.

60. Soares da Costa D, Reis RL, Pashkuleva I. Sulfation of glycosaminoglycans and its implications in human health and disorders. Annu Rev Biomed Eng. 2017; 19(1):1–26.

61. Kreuger J, Matsumoto T, Vanwildemeersch M, Sasaki T, Timpl R, Claesson-Welsh L, Spillmann D, Lindahl U. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J. 2002 Dec 22;1(23):6303–11.

62. Kjellén L, Lindahl U. Specificity of glycosaminoglycan-protein interactions. Curr Opin Struct Biol. 2018;50:101–8.

63. Bojarski KK, Sieradzan AK, Samsonov SA. Molecular dynamics insights into protein-glycosaminoglycan systems from microsecond-scale simulations. Biopolymers. 2019;110(7):e23252.

64. Uciechowska-Kaczmarzyk U, Babik S, Zsila F, Bojarski KK, Beke-Somfai T, Samsonov SA. Molecular dynamics-based model of VEGF-A and its heparin interactions. J Mol Graph Model. 2018;82:157–66.

65. Potthoff J, Bojarski KK, Kohut G, Lipska AG, Liwo A, Kessler E, Ricard-Blum S, Samsonov SA. Analysis of procollagen C-proteinase enhancer-1/glycosaminoglycan binding sites and of the potential role of calcium ions in the interaction. Int J Mol Sci. 2019 Oct 10;20(20):5021.

66. Vallet SD, Miele AE, Uciechowska-Kaczmarzyk U, Liwo A, Duclos B, Samsonov SA, Ricard-Blum S. Insights into the structure and dynamics of lysyl oxidase propeptide, a flexible protein with numerous partners. Sci Rep. 2018 Aug 6;8(1):11768.

67. Uciechowska Kaczmarzyk -U, Chauvot de Beauchene I, Samsonov SA. Docking software performance in protein-glycosaminoglycan systems. J Mol Graph Model. 2019;90:42–50.

68. Sankaranarayanan NV, Nagarajan B, Desai UR. So you think computational approaches to understanding glycosaminoglycan-protein interactions are too dry and too rigid? Think Again! Curr Opin Struct Biol. 2018;50: 91–100.

69. Ori A, Wilkinson MC, Fernig DG. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem. 2011 Jun 3;286(22): 19892–904.

70. Ricard-Blum S. Protein–glycosaminoglycan interaction networks: focus on heparan sulfate. Perspect Sci. 2017 Jan 1;11:62–9.

71. Djerbal L, Lortat-Jacob H, Kwok J. Chondroitin sulfates and their binding molecules in the central nervous system. Glycoconj J. 2017;34(3):363–76.

72. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019 Jan 8;47(D1): D506–15.

73. The Gene Ontology Consortium. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019 Jan 8;47(D1):D330–8.

74. Day AJ, Milner CM. TSG-6: a multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol. 2019;78–79:60–83.

75. Winograd-Katz SE, Fässler R, Geiger B, Legate KR. The integrin adheshome: from genes and proteins to human disease. Nat Rev Mol Cell Biol. 2014;15(4):273–88.

76. Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, Colby G, Gebreab F, Gygi MP, Parzen H, Szpyt J, Tam S, Zarraga G, Pontano-Vaites L, Swarup S, White AE, Schweppe DK, Rad R, Erickson BK, Obar RA, Guruharsha KG, Li K, Artavanis-Tsakonas S, Gygi SP, Harper JW. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505–9.

77. Pathan M, Keerthikumar S, Ang C-S, Gangoda L, Quek CYJ, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, Bacic A, Hill AF, Stroud DA, Ryan MT, Agbinya JI, Mariadason JM, Burgess AW, Mathivanan S. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15(15):2597–601.

78. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Viteri G, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. The reactome pathway knowledgebase. Nucleic Acids Res. 2018 Jan 4;46(D1):D649–55.

79. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. The reactome pathway knowledgebase. Nucleic Acids Res. 2020 Jan 8;48(D1):D498–503.

80. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, Jupe SC, Kok CY, Noble K, Ponting L, Ramshaw CC, Rye CE, Speedy HE, Stefancsik R, Thompson SL, Wang S, Ward S, Campbell PJ, Forbes SA. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019 Jan 8;47(D1):D941–7.

81. Ricard-Blum S, Lisacek F. Glycosaminoglycanomics: where we are. Glycoconj J. 2017;34(3):339–49.

82. Shao C, Shi X, Phillips JJ, Zaia J. Mass spectral profiling of glycosaminoglycans from histological tissue surfaces. Anal Chem. 2013 Nov 19;85(22):10984–91.

83. Zaia J. Glycosaminoglycan glycomics using mass spectrometry. Mol Cell Proteomics. 2013;12(4):885–92.

84. Raghunathan R, Sethi MK, Klein JA, Zaia J. Proteomics, glycomics, and glycoproteomics of matrisome molecules. Mol Cell Proteomics. 2019;18(11):2138–48.
85. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. *Chem Biol Drug Des.* 2008;72(6):455–82.

86. Ricard-Blum S, Féraud O, Lortat-Jacob H, Rencurosi A, Fukai N, Dkhissi F, Vittet D, Imberty A, Olsen BR, van der Rest M. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. *J Biol Chem.* 2004 Jan 23;279(4):2927–36.

87. Stelling MP, Motta JM, Mashid M, Johnson WE, Pavão MS, Farrell NP. Metal ions and the extracellular matrix in tumor migration. *FEBS J.* 2019;286(15):2950–64.

88. Gopal S. Syndecans in inflammation at a glance. *Front Immunol.* 2020;11:227.

89. Mitsou I, Multhaupt HAB, Couchman JR. Proteoglycans, ion channels and cell-matrix adhesion. *Biochem J.* 2017 May 25;474(12):1965–79.